Clinical effectiveness of brinzolamide 1%–brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension

Figures & data

Table 1 Published clinical trials evaluating fixed-combination brinzolamide and brimonidine

	Patients (n)	Dosage and duration	Change in intraocular pressure (mmHg) from baseline
			BBFC	Brinzolamide	Brimonidine
Nguyen et al^Citation23	n=679	3 times daily for 3 months	5.4–8.4	4.2–5.7	3.1–6.5
	1:1:1
	1) BBFC (n=218)
	2) brinzolamide 1% (n=229)
	3) brimonidine 0.2% (n=232)
Whitson et al^Citation24,*	n=679	3 times daily for 6 months	5.4–8.4	4.2–5.7	3.1–6.5
	1:1:1
	1) BBFC (n=218)
	2) brinzolamide 1% (n=229)
	3) brimonidine 0.2% (n=232)
Katz et al^Citation25	n=649	3 times daily for 3 months	7.1–8.8	4.3–6.2	3.5–5.8
	1:1:1
	1) BBFC (n=209)
	2) brinzolamide 1% (n=224)
	3) brimonidine 0.2% (n=216)
Realini et al^Citation26,#	n=1,350	3 times daily for 3 months	5.5–8.9	4.2–5.9	3.3–6.9
	1:1:1
	1) BBFC (n=437)
	2) brinzolamide 1% (n=458)
	3) brimonidine 0.2% (n=455)
Aung et al^Citation27	n=559	2 times daily for 6 months	7.2–9.3	5.5–7.2	5.2–8.1
	1:1:1
	1) BBFC (n=193)
	2) brinzolamide 1% (n=192)
	3) brimonidine 0.2% (n=175)
Gandolfi et al^Citation28	n=890	2 times daily for 6 months	7.3–9.3	7.7–9.4
	1:1
	1) BBFC (n=451)
	2) brinzolamide 1% plus
	brimonidine 0.2% (n=439)

Notes:

* Three-month extension of Nguyen et al;²³

# pooled data of Nguyen et al²³ and Katz et al.²⁵

Abbreviation: BBFC, brinzolamide 1% and brimonidine 0.2% fixed combination.

Table 2 List of adverse effects from all studies (pooled data)^22,24,26,27

	BBFC (n=1,077)	Brinzolamide (n=646)	Brimonidine (n=627)
Ocular hyperemia	36 (3.3%)	4 (0.6%)	8 (1.7%)
Eye pain	27 (2.5%)	11 (1.7%)	5 (0.8%)
Dysgeusia	39 (3.6%)	42 (6.5%)	3 (0.3%)
Blurred vision	41 (3.8%)	31 (4.8%)	4 (0.4%)
Dry mouth	31 (2.8%)	2 (0.3%)	20 (3.2%)
Conjunctivitis	16 (4.8%)	0	8 (1.2%)
Eye pruritus	25 (2.3%)	8 (1.2%)	4 (1.1%)
Allergic conjunctivitis	37 (2.4%)	2 (0.3%)	10 (1.5%)
Eye allergy	22 (2.2%)	0	7 (1.1%)
Eye irritation	30 (2.7%)	10 (1.5%)	13 (2.1%)
Conjunctival hyperemia	17 (1.5%)	8 (1.2%)	9 (1.4%)
Dry eyes	7 (1.1%)	5 (0.8%)	10 (1.6%)

Abbreviation: BBFC, brinzolamide 1% and brimonidine 0.2% fixed combination.

NguyenQHMcMenemyMGRealiniTWhitsonJTGoodeSMPhase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%/brimonidine 0.2%J Ocul Pharmacol Ther20132929029723425430

 PubMed Web of Science ®Google Scholar

WhitsonJTRealiniTNguyenQHMcMenemyMGGoodeSMSix-month results from a phase III randomized trial of fixed-combination brinzolamide 1% + brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertensionClin Ophthalmol201371053106023766627

 PubMedGoogle Scholar

KatzGDubinerHSamplesJVoldSSallKThree month randomized trial of fixed combination brinzolamide, 1%, and brimonidine, 0.2%JAMA Ophthalmol201313172473023579344

 PubMed Web of Science ®Google Scholar

RealiniTNguyenQHKatzGDubinerHFixed-combination brinzolamide 1%/brimonidine 0.2% vs monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3 studiesEye (Lond)20132784184723640612

 PubMed Web of Science ®Google Scholar

AungTLaganovskaGHernandez ParedesTJBranchJDTsorbatzoglouAGoldbergITwice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertensionOphthalmology20141212348235525064721

 PubMed Web of Science ®Google Scholar

GandolfiSALimJSanseauACParra RestrepoJCHamacherTRandomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertensionAdv Ther2014311213122725430900

 PubMed Web of Science ®Google Scholar

FellmanRLSullivanEKRatliffMComparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trialOphthalmology2002109998100811986110

 PubMed Web of Science ®Google Scholar